Samsung BiologicsLtd (A207940) Stock Overview
Together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for A207940 from our risk checks.
A207940 Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Samsung Biologics Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,601,000.00 |
| 52 Week High | ₩1,987,000.00 |
| 52 Week Low | ₩1,480,000.00 |
| Beta | 0 |
| 1 Month Change | 1.01% |
| 3 Month Change | -17.77% |
| 1 Year Change | -0.74% |
| 3 Year Change | 32.65% |
| 5 Year Change | 28.24% |
| Change since IPO | 623.11% |
Recent News & Updates
Shareholder Returns
| A207940 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 1.9% | 2.2% | 5.8% |
| 1Y | -0.7% | 7.6% | 138.3% |
Return vs Industry: A207940 underperformed the KR Life Sciences industry which returned 7.6% over the past year.
Return vs Market: A207940 underperformed the KR Market which returned 138.3% over the past year.
Price Volatility
| A207940 volatility | |
|---|---|
| A207940 Average Weekly Movement | 6.1% |
| Life Sciences Industry Average Movement | 10.0% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.6% |
Stable Share Price: A207940 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A207940's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 4,770 | John Chongbo Rim | samsungbiologics.com |
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance.
Samsung Biologics Co.,Ltd. Fundamentals Summary
| A207940 fundamental statistics | |
|---|---|
| Market cap | ₩74.11t |
| Earnings (TTM) | ₩1.61t |
| Revenue (TTM) | ₩4.56t |
Is A207940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A207940 income statement (TTM) | |
|---|---|
| Revenue | ₩4.56t |
| Cost of Revenue | ₩2.06t |
| Gross Profit | ₩2.50t |
| Other Expenses | ₩886.51b |
| Earnings | ₩1.61t |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 22, 2026
| Earnings per share (EPS) | 34.87k |
| Gross Margin | 54.88% |
| Net Profit Margin | 35.43% |
| Debt/Equity Ratio | 12.3% |
How did A207940 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/18 05:19 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Samsung Biologics Co.,Ltd. is covered by 46 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nithya Balasubramanian | Bernstein |
| Girish Bakhru | BofA Global Research |
| Hyeryeong Kim | CGS International |